Table 1. Clinical differences between discovery and validation studies.

		Studies
		Discovery	Validation
		TCGA	Tothill	Yoshihara
N		503	240	260
Age	Mean	59.8	60.2	NA
Stage	I, II	24	9	0
	III, IV	463	215	260	*
Grade	1	4	5	0
	2,3	473	218	260	**
Cytoreduction	Optimal	102	53	103
	Suboptimal	348	140	157	+
Follow Up
OS	Median	30	28	41.5
PFS	Median	13.2	14	19

*excludes Yoshihara data, p-value  = .001597 when including Yoshihara data.

⁺definition of optimal/suboptimal not clearly defined in Yoshihara data.